FDA Adverse Event Malfunction Summary report: N

ELECSYS ACTH

MDR report key: 17791014 · Received September 21, 2023

Report

Report Number
1823260-2023-03056
Event Type
Malfunction
Date Received
September 21, 2023
Date of Event
August 14, 2023
Report Date
October 16, 2025
Manufacturer
ROCHE DIAGNOSTICS
Product Code
CKG
PMA / PMN Number
K060585
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
JA
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

BASED ON THE CURRENT INFORMATION, THE INVESTIGATION WAS UNABLE TO DETERMINE A SPECIFIC ROOT CAUSE. SAMPLE TYPE AND SAMPLE STABILITY ISSUES COULD NOT BE EXCLUDED. THE SAMPLES WERE REPEATEDLY FROZEN WHICH IS ALLOWED ONLY ONCE PER PRODUCT LABELING AND BEYOND THE STABILITY PER DOCUMENTED IN PRODUCT LABELING WHEN TESTED FOR THE PRELIMINARY INVESTIGATION. CALIBRATION AND QC DATA DO NOT SUGGEST ANY REAGENT ISSUE.

Additional Manufacturer Narrative · 0

G1 CONTACT OFFICE-MANUFACTURING SITE WAS UPDATED.

Additional Manufacturer Narrative · 0

THE SERIAL NUMBER OF THE COBAS 8000 CORE ANALYZER WAS REQUESTED BUT WAS NOT PROVIDED. THE INVESTIGATION IS ONGOING.

Description of Event or Problem · 0

THERE WAS AN ALLEGATION OF QUESTIONABLE ACTH ELECSYS E2G RESULTS FROM THE COBAS 8000 CORE ANALYZER. THE RESULTS FROM THE CUSTOMER OVER TIME AFTER LOADING FOR ACTH: 0 MINUTES (SAMPLE 1): 100 PG/ML. 15 MINUTES (SAMPLE-2): 113 PG/ML. 30 MINUTES (SAMPLE-3): 110 PG/ML. ON 7-SEP-2023, THE PRELIMINARY INVESTIGATION TESTED THE SAMPLES ON A COBAS E801 MODULE: SAMPLE 1: 53.0 PG/ML. SAMPLE 2: 71.7 PG/ML. SAMPLE 3: 65.6 PG/ML. BASED ON THE RESULTS, THE CUSTOMER SUSPECTED A NON-SPECIFIC REACTION IN ROCHE ASSAY. NO INFORMATION WAS PROVIDED TO DETERMINE IF THE QUESTIONABLE RESULTS WERE REPORTED OUTSIDE OF THE LAB.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1446817 ELECSYS ACTH ADRENOCORTICOTROPIC HORMONE (ACTH) TEST SYSTEM CKG ROCHE DIAGNOSTICS ASKU

Patients

Seq Age Sex Outcome Treatment
1 NA Female